Status:
COMPLETED
Antibody Response to Influenza Vaccine in Patients With Sarcoidosis
Lead Sponsor:
Shahid Beheshti University of Medical Sciences
Conditions:
Pulmonary Sarcoidosis
Eligibility:
All Genders
20-60 years
Brief Summary
The purpose of this study is to determine the efficacy of influenza vaccine (antibody response) in patients with sarcoidosis.
Detailed Description
Sarcoidosis is a multisystem disease with unclear etiology characterized by the presence of noncaseating granuloma\[1\]. T helper cells response is exaggerated at the site of disease and cellular immu...
Eligibility Criteria
Inclusion
- Sarcoidosis patients:
- Patients with relevant clinical, radiologic and histologic features of sarcoidosis (all stages).
- Signed informed consent.
Exclusion
- Organ failure (kidney, heart, liver).
- Collagen vascular diseases.
- Diabetes.
- Contraindications of vaccine (Egg allergy).
- Patients who receive high dose (\> 60 mg/day) steroid therapy.
- Any acute disease.
- Conditions accompanied by immunosuppression (like organ transplantation, HIV).
- Any psychological disease that interferes with regular follow-up.
- Inoculation with influenza vaccine within the past 5 years.
Key Trial Info
Start Date :
December 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT00828828
Start Date
December 1 2008
End Date
May 1 2009
Last Update
May 21 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shahid Modarres Hospital
Tehran, Iran, 1998734383